Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
13.50
-0.34 (-2.46%)
Aug 31, 2026, 9:55 AM EDT - Market open
Bioventus Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 581.85 | 568.09 | 573.28 | 512.35 | 512.12 | 430.9 | |
Revenue Growth | 3.14% | -0.91% | 11.89% | 0.04% | 18.85% | 34.17% |
Cost of Revenue | 182.4 | 179.93 | 185.05 | 184.15 | 181.04 | 128.19 |
Gross Profit | 399.45 | 388.16 | 388.23 | 328.19 | 331.08 | 302.71 |
Selling, General & Admin | 322.42 | 313.98 | 330 | 303.88 | 332.13 | 254.25 |
Research & Development | 11.57 | 12.11 | 13.95 | 13.45 | 23.85 | 19.04 |
Operating Expenses | 338.84 | 331.82 | 351.6 | 326.17 | 365.74 | 281.66 |
Operating Income | 60.61 | 56.34 | 36.63 | 2.03 | -34.66 | 21.05 |
Interest Expense | -19.88 | -26.49 | -38.79 | -40.68 | -18.42 | -3.84 |
Interest & Investment Income | - | - | - | - | 6.4 | 2.73 |
Earnings From Equity Investments | - | - | - | - | - | -1.87 |
Currency Exchange Gain (Loss) | 3.99 | 1.98 | 1.31 | 0.35 | -0.25 | -0.13 |
Other Non Operating Income (Expenses) | -3.43 | -3.43 | 0.34 | 0.94 | 0.77 | 1.91 |
EBT Excluding Unusual Items | 41.29 | 28.4 | -0.52 | -37.36 | -46.16 | 19.85 |
Merger & Restructuring Charges | -2.27 | -2.24 | 0.05 | -0.84 | -6.78 | -2.49 |
Impairment of Goodwill | - | - | - | - | -124.7 | - |
Gain (Loss) on Sale of Investments | - | - | - | - | -10.29 | -7.04 |
Gain (Loss) on Sale of Assets | 0 | -0.08 | -0.29 | -3.58 | - | - |
Asset Writedown | - | - | -36.36 | -78.62 | - | - |
Legal Settlements | -0.06 | -0.05 | -13.8 | - | - | - |
Other Unusual Items | -0.33 | -0.33 | -1.42 | -0.72 | -1.1 | -0.83 |
Pretax Income | 38.64 | 25.71 | -52.34 | -121.11 | -189.03 | 9.49 |
Income Tax Expense | -22.84 | -1.57 | -5.29 | 0.09 | -44.37 | -1.97 |
Earnings From Continuing Operations | 61.48 | 27.27 | -47.05 | -121.2 | -144.65 | 11.45 |
Earnings From Discontinued Operations | - | - | - | -59.49 | -54.79 | -1.87 |
Net Income to Company | 61.48 | 27.27 | -47.05 | -180.69 | -199.44 | 9.59 |
Minority Interest in Earnings | -7.01 | -4.54 | 10.92 | 24.46 | 40.73 | 9.79 |
Net Income | 54.46 | 22.73 | -36.13 | -156.23 | -158.7 | 19.38 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 25.98 |
Net Income to Common | 54.46 | 22.73 | -36.13 | -156.23 | -158.7 | -6.6 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 67 | 67 | 65 | 63 | 61 | 45 |
Shares Outstanding (Diluted) | 70 | 69 | 65 | 63 | 61 | 45 |
Shares Change | 5.97% | 6.77% | 3.03% | 2.05% | 35.00% | 828.01% |
EPS (Basic) | 0.81 | 0.34 | -0.56 | -2.49 | -2.59 | -0.15 |
EPS (Diluted) | 0.78 | 0.33 | -0.56 | -2.49 | -2.59 | -0.15 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 94.29 | 72.11 | 37.79 | 7.98 | -25.06 | 9.47 |
Free Cash Flow Per Share | 1.35 | 1.05 | 0.58 | 0.13 | -0.41 | 0.21 |
Gross Margin | 68.65% | 68.33% | 67.72% | 64.06% | 64.65% | 70.25% |
Operating Margin | 10.42% | 9.92% | 6.39% | 0.40% | -6.77% | 4.88% |
Profit Margin | 9.36% | 4.00% | -6.30% | -30.49% | -30.99% | -1.53% |
Free Cash Flow Margin | 16.20% | 12.69% | 6.59% | 1.56% | -4.89% | 2.20% |
EBITDA | 80.15 | 77.64 | 55.76 | 28.85 | -4.68 | 41.52 |
EBITDA Margin | 13.77% | 13.67% | 9.73% | 5.63% | -0.91% | 9.64% |
D&A For EBITDA | 19.54 | 21.3 | 19.14 | 26.82 | 29.97 | 20.47 |
EBIT | 60.61 | 56.34 | 36.63 | 2.03 | -34.66 | 21.05 |
EBIT Margin | 10.42% | 9.92% | 6.39% | 0.40% | -6.77% | 4.88% |
Advertising Expenses | - | 4.14 | 4.42 | 3.85 | 5.2 | 3.87 |